Skip to main content
Evaxion narrows Q3 loss to $3.5 million
Image for illustrative purposes only. Not a real photo.

Evaxion narrows Q3 loss to $3.5 million

By

Key points

  • Evaxion (NASDAQ:EVAX) reported a third-quarter 2026 net loss of US$3.5 million, compared with net income of US$4.6 million a year earlier.
  • Quarterly revenue fell to zero from US$7.492 million, while share sales generated US$2.2 million in gross proceeds.
  • The company is prioritizing cancer vaccine development, with a Phase I trial application for EVX-04 targeted by the end of 2026.

Evaxion (NASDAQ:EVAX) reported a third-quarter 2026 net loss of US$3.5 million, compared with net income of US$4.6 million in the same period last year, as it refocused its research activities on cancer vaccines.

Quarterly revenue fell to zero from US$7.492 million a year earlier, although the net loss narrowed from US$3.7 million in the second quarter of 2026.

The company reported that its personalized cancer vaccine candidate EVX-01 demonstrated 89% vaccine target precision in a Phase II advanced melanoma study, with sustained immune and clinical responses observed at the three-year follow-up.

Evaxion raised US$2.2 million in gross proceeds from share sales and expects its available cash to fund operations toward the end of 2027.

Evaxion said it remains on track to file a Phase I clinical trial application for EVX-04 by the end of 2026 and plans to advance another cancer vaccine candidate, EVX-05, toward clinical development.

The company is making cancer vaccines its primary research focus, while further development of its infectious disease programmes will depend on securing external partner funding.


Frequently asked questions